The DOI matches its Crossref record; 90 of the 90 references it cites were found in a registry or an index; 43 of the 99 sources its claims cite were checked for support.
GLP-1 agonists in the treatment of chronic kidney disease in type 2 diabetes and obesity
Open accessAbstract
Glucagon-like peptide-1 (GLP-1) was initially considered to be a hormone with a predominant role in regulating glucose metabolism by inducing insulin secretion, reducing glucagon secretion, and ameliorating insulin resistance, with the last effect being largely dependent on the induction of weight loss. In more recent years, the role of this peptide beyond metabolism has progressively been explored, including its impact on kidney physiology and kidney clinical outcomes in people with obesity with or without diabetes. Indeed, despite only modest expression of the GLP-1 receptor in the kidney, the renoprotective actions of GLP-1 and its receptor agonists have become an area of intensive investigation. This Review appraises the current status of GLP-1 peptide and its receptor agonists and focuses on the preclinical as well as recent seminal clinical findings defining the kidney benefits conferred by GLP-1 receptor agonist treatment in people living with type 2 diabetes and obesity.
Overview
CoChat Summary
## TL;DR
This review summarizes evidence that GLP-1 receptor agonists have kidney benefits in type 2 diabetes and obesity, with effects seen in albuminuria, eGFR decline, and hard kidney outcomes. It also reviews proposed mechanisms and notes that benefits may be partly indirect through improvements in glycemia, weight, blood pressure, and cardiovascular function.
## Key findings
- In cardiovascular outcome trials, GLP-1 receptor agonists consistently reduced urinary albumin-to-creatinine ratios by 20%–40% and reduced new-onset macroalbuminuria in people with T2D.
- In the dedicated FLOW trial, 3,533 participants with T2D and CKD were randomized to semaglutide 1.0 mg weekly or placebo; semaglutide lowered the risk of the primary composite kidney outcome by 24%, the kidney-specific components by 21%, and reduced annual eGFR decline by 1.16 mL/min/1.73 m² versus placebo.
- In SELECT, among participants without diabetes, semaglutide reduced the composite kidney endpoint by 22%; at 104 weeks, eGFR declined less with semaglutide (–0.86 mL/min/1.73 m²) than with placebo (–1.61 mL/min/1.73 m²).
- In SMART, semaglutide 2.4 mg weekly reduced UACR by 52% at 24 weeks in people with overweight/obesity and non-diabetic CKD; a post hoc analysis of SURMOUNT-1 also found tirzepatide reduced UACR in overweight/obese people without T2D.
## Methods
- This is a Review article that appraises preclinical, human physiology, and clinical trial evidence on GLP-1 receptor agonists and kidney outcomes in T2D and obesity.
- The evidence base includes CVOTs, the FLOW kidney outcome trial, obesity/CKD trials such as SELECT and SMART, and mechanistic studies using kidney biopsy, single-cell sequencing, and multiparametric MRI.
- The article synthesizes findings from randomized trials, post hoc and prespecified secondary analyses, and preclinical/physiologic studies rather than presenting original study data.
## Limitations
- The review states that earlier CVOT kidney analyses did not specifically include patients with kidney disease, and the number of hard kidney outcomes was too low to make definitive conclusions.
- It notes that the GLP-1 receptor is only modestly expressed in the kidney, and the precise mechanism of kidney benefit remains uncertain.
- Evident from the text: several mechanistic conclusions are based on heterogeneous studies with inconsistent results across human physiology experiments, and some cited findings are post hoc or from secondary endpoints rather than primary kidney-outcome trials.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
39 Valid · 0 Not valid · 46 Not checked · 28 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“For example, the effects of GLP-1 receptor agonists on blood pressure appear to be rather modest, as recently summarized (21), and are not in line with kidney outcomes observed with other agents that provide a similar reduction in blood pressure.”
§ GLP-1 agonists in the treatment of chronic kidney disease in type 2 diabetes and obesity > Modulation of kidney risk factors underlying renoprotective effects
What the sources say
- Supportedcites [21] source
The “BP lowering effects with GLP1-RAs” section reports small systolic blood-pressure reductions, including 0.8 mm Hg with lixisenatide and 1.2 mm Hg with liraglutide. These figures support the cited characterization of the blood-pressure effects as modest. The citation is attached to that characterization, not to the citing authors’ subsequent comparison with kidney outcomes. (LLM, conf=0.91)
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“A recent meta-analysis confirmed little heterogeneity in terms of outcomes in the FLOW trial and in the relevant CVOTs (16).”
§ GLP-1 agonists in the treatment of chronic kidney disease in type 2 diabetes and obesity > Renoprotective effects of GLP-1 receptor agonists: clinical trials
What the sources say
- Partly supportedcites [16] sourceExperimental — accuracy not yet measured
The Discussion reports 0% heterogeneity for kidney failure across trials, including FLOW, and the Cardiovascular Outcomes section says MACE treatment effects were consistent across trials. But the reported MACE I² was 49.75% in participants with type 2 diabetes—near the paper’s threshold for moderate heterogeneity—and the paper reports significant heterogeneity for nonfatal myocardial infarction by diabetes status. Thus, “little heterogeneity” is supported for some outcomes, not outcomes generally. (LLM, conf=0.84)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Moreover, statistical correction for changes in body weight did not attenuate the albuminuria-lowering effects of GLP-1 receptor agonists in the CVOTs (23).”
§ GLP-1 agonists in the treatment of chronic kidney disease in type 2 diabetes and obesity > Modulation of kidney risk factors underlying renoprotective effects
What the sources say
- Partly supportedcites [23] sourceExperimental — accuracy not yet measured
The Results report that body weight mediated 9% of the composite kidney benefit in LEADER and none in SUSTAIN 6; the Discussion concludes that body weight was not an important mediator in either trial. The Methods define that outcome as including, but not limited to, new-onset macroalbuminuria. The paper therefore supports the broad point about kidney benefit, but it does not report a weight-corrected analysis of albuminuria lowering specifically, and the claim’s unqualified ‘did not attenuate’ overlooks the 9% estimate in LEADER. (LLM, conf=0.86)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Overall, between 5% and 10% of subjects stopped treatment in GLP-1 receptor agonist trials because of side effects (17).”
§ GLP-1 agonists in the treatment of chronic kidney disease in type 2 diabetes and obesity > Renoprotective effects of GLP-1 receptor agonists: clinical trials
What the sources say
- Partly supportedcites [17] sourceExperimental — accuracy not yet measured
The Gastrointestinal (GI) Adverse Effects section says GI complaints caused discontinuation in semaglutide phase-3 trials at rates up to 12%, and estimates that approximately 10% of patients discontinue semaglutide because of GI complaints using trial and real-world data. It does not establish a 5%–10% discontinuation range across GLP-1 receptor agonist trials generally. (LLM, conf=0.87)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The pro-oxidant enzyme NAD(P)H oxidase 4 (NOX4) has been shown to promote kidney injury (60), and in mice its expression can be attenuated by treatment with exendin-4 (61).”
§ GLP-1 agonists in the treatment of chronic kidney disease in type 2 diabetes and obesity > Postulated direct renoprotective effects of GLP-1 receptor agonists: preclinical evidence In order to define the intrakidney mode of action of GLP-1 receptor agonists, numerous preclinical studies have been performed, predominantly, but not exclusively, in models of DKD. Findings from some of these models have been difficult to interpret since in certain studies the GLP-1 receptor agonists concomitantly affected glucose homeostasis, which is itself usually associated with reduced kidney injury, independent of the mode of glucose lowering. However, one of the earliest studies, performed more than 15 years ago, administered the GLP-1 receptor agonist exendin-4 to db/db mice, a model of T2D (56). Indeed, this agonist was associated with reduced kidney injury. There were modest effects on glucose tolerance without a major effect on fasting glucose concentrations or glycated hemoglobin. These early findings provided initial critical evidence that GLP-1 analogs could potentially be renoprotective, independent of their effects on blood glucose concentrations. To further explore such a possibility, a subsequent preclinical study was performed in insulin-deficient streptozotocin (STZ) diabetic rats with exendin-4 (57). In that study, exendin-4 not only ameliorated albuminuria but conferred kidney structural benefits including reduced glomerular hypertrophy and mesangial matrix expansion in the absence of an effect on body weight, blood pressure, or circulating glucose concentrations. Concomitant effects including reduced kidney inflammation and fibrosis were also observed. This effect on macrophage infiltration has become one of the most prominent features of GLP-1 receptor agonism, as demonstrated in numerous subsequent experimental studies. To further define how GLP-1 receptor agonists act in the kidney at a molecular level, researchers have explored various pathways implicated in kidney injury particularly in the setting of diabetes. DKD is considered to occur as a result of an interplay between metabolic and hemodynamic factors (58), with many of the putative pathways leading to injury having already been delineated (59). Therefore, what have been of particular interest are the effects of GLP-1 on these clearly defined pathways that promote kidney injury, such as oxidative stress, fibrosis via enhanced prosclerotic factor action, and inflammation. The pro-oxidant enzyme NAD(P)H oxidase 4 (NOX4) has been shown to promote kidney injury (60), and in mice its expression can be attenuated by treatment with exendin-4 (61). This effect on renal NOX4 was further examined in STZ diabetic rats treated with liraglutide (62). In that study, GLP-1 agonist treatment led to a reduction in oxidative stress, as assessed by measurement of urinary 8-hydroxy-2-deoxyguanosine and renal dihydroethidium staining. To determine whether the reduction in oxidative stress was mediated directly by GLP-1 receptor activation, complementary in vitro studies in human mesangial cells were performed. Liraglutide inhibited NOX4 enzymatic activity, and this effect could be blocked by incubation with a protein kinase inhibitor or an adenylate cyclase inhibitor (62). Such effects are consistent with a role for the G protein–coupled GLP-1 receptor.
What the sources say
- Supportedcites [60] source
The Abstract reports that deleting Nox4 protected diabetic mice from glomerular injury and identifies Nox4 as a source of ROS responsible for kidney injury in diabetes. This supports the cited claim that NOX4 has been shown to promote kidney injury; the separate exendin-4 claim is attributed to another citation. (LLM, conf=0.93)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
79 more claims · 22 with their cited sources checked
Create a free account to see all 113 claims and to verify the 12 references still open.
- It may state two separate claims as one. 22
- The quote only partly states this claim. 2
- Probably not a substantial claim. 6
Citations
Cites
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307563 · Cited by 3,236 · cited 1×
“In the SELECT trial, 2.4 mg semaglutide weekly or placebo was administered to over 16,000 patients with overweight/obesity and established cardiovascular disease (85).”
InfluentialThe biology of incretin hormones
Drucker, D. J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.004 · Cited by 2,210 · cited 1×
“GLP-1’s actions to improve glucose metabolism are additionally driven by the reduction of hyper-glucagonemia (5).”
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
Perkovic, V., Tuttle, K. R., Rossing, P., Mahaffey, K. W., Mann, J. F. E., Bakris, G., Baeres, F. M. M., Idorn, T., Bosch-Traberg, H., Lausvig, N. L., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2403347 · Cited by 2,099
Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
Flint, A., Raben, A., Astrup, A., & Holst, J. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci990 · Cited by 1,402 · cited 1×
“GLP-1 also plays a key role in the regulation of body weight via various well-characterized mechanisms, including delayed gastric emptying and intestinal transit, and actions in the central nervous system that reduce appetite by stimulating satiety, in particular related to hedonic feeding (6, 7).”
Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
Jastreboff, A. M., Kaplan, L. M., Frías, J. P., Wu, Q., Du, Y., Gurbuz, S., Coskun, T., Haupt, A., Milicevic, Z., & Hartman, M. L. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2301972 · Cited by 1,174 · cited 9×
“Preliminary data point toward beneficial effects of GIP agonism, as reported in findings from the SURPASS program that tirzepatide reduced UACR and slowed down eGFR declined in comparison with both placebo (53) and comparator drugs including insulin glargine (74, 75).”
InfluentialMacrophages: versatile players in renal inflammation and fibrosis
Tang, P. M.-K., Nikolic-Paterson, D. J., & Lan, H.-Y. (2019) · Nature Reviews Nephrology · doi:10.1038/s41581-019-0110-2 · Cited by 1,033 · cited 1×
“There is also increasing evidence that these two macrophage populations produce cytokines and chemokines that can create a feed-forward cycle to accelerate intrarenal inflammation in various kidney diseases, including in diabetes (65).”
Molecular Understanding of Hyperglycemia's Adverse Effects for Diabetic Complications
Sheetz, M. J. (2002) · JAMA · doi:10.1001/jama.288.20.2579 · Cited by 1,002 · cited 1×
“DKD is considered to occur as a result of an interplay between metabolic and hemodynamic factors (58), with many of the putative pathways leading to injury having already been delineated (59).”
Targeting the progression of chronic kidney disease
Ruiz-Ortega, M., Rayego-Mateos, S., Lamas, S., Ortiz, A., & Rodrigues-Diez, R. R. (2020) · Nature Reviews Nephrology · doi:10.1038/s41581-019-0248-y · Cited by 979 · cited 1×
“Both kidney cells and recruited immune cells of the innate (M1 macrophages) and the adaptive (CD4 + and CD8 + T cells) immune systems produce proinflammatory factors that damage the kidney (42).”
Control of glomerular hypertension limits glomerular injury in rats with reduced renal mass.
Anderson, S., Meyer, T. W., Rennke, H. G., & Brenner, B. M. (1985) · Journal of Clinical Investigation · doi:10.1172/jci112013 · Cited by 932 · cited 7×
“A prespecified secondary analysis of SELECT participants without diabetes showed that semaglutide reduced the composite kidney endpoint by 22% (86), with 75% of participants on RAAS blocker therapy at baseline.”
InfluentialThorens, B. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.18.8641 · Cited by 906 · cited 1×
“…receptor agonists act directly on the kidney despite very low levels of expression of the only known GLP-1 receptor, which was cloned more than 30 years ago (64), remains a major question, in part due to the limited ability to accurately measure GLP-1 receptor protein expression in the kidney.”
Research works printed but not linked: 3
- Cherney, Rationale, design and baseline characteristics of REMODEL, a mechanism-of-action trial with semaglutide in people with type 2 diabetes and chronic kidney disease, Nephrol Dial Transplant
- Brown, 1970, Cleavage of a gastric inhibitory polypeptide with cyanogen bromide and the physiological action of the C-terminal fragment, J Physiol, 210, 52
- Rosenstock, Orforglipron, an oral small-molecule GLP-1 receptor agonist, in early type 2 diabetes, N Engl J Med
Cited by
Should Incretin Agonist-Based Drugs be Considered for First Line Antihypertensive Therapy?
Kylies, D., Dreher, L., & Wenzel, U. O. (2026) · Current Hypertension Reports · doi:10.1007/s11906-026-01374-7 · Cited by 2
“Proposed mechanisms include mechanical compression of renal vessels and nerves, induction of glomerular hyper-filtration, activation of the renin–angiotensin–aldosterone system, and promotion of inflammation through local cyto - kine release [26 ].”
Kidney angiopoietin-like protein 4 regulates fibrotic responses in diabetic kidney disease
Srivastava, S. P., Arora, A., Hamed, M., Urval, A., Dupati, A., Xia, S., Yoshida, S., & Inoki, K. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1803412 · Cited by 1
“GLP-1 RAs and SGLT2is provide cardio-renal protection that differs from renin-angiotensin system inhibition, providing an additional layer of DKD treatment (Colhoun et al., 2024; Cooper and van Raalte, 2025; Fioretto et al., 2016; Bae, 2025).”
Li, J., Liang, J., Zhang, W., He, J., & Ye, X. (2026) · Diabetes Therapy · doi:10.1007/s13300-026-01872-6 · Cited by 5
“Notably, the National Medical Products Administration (NMPA) has approved semaglutide for chronic kidney disease (CKD) [40], making it the first GLP-1 RA in China with indications for glycemic control, cardiovascular protection, and renal protection [41].”
Zbârcea, C. E., Marineci, C., Valeanu, A., Chiriţă, C., & Șeremet, O. C. (2026) · Diabetology · doi:10.3390/diabetology7060108 · Cited by 3
“These agents slow kidney disease progression, support neuroprotection in neurodegenerative disorders, and semaglutide is approved for chronic kidney disease and metabolic dysfunction-associated steatohepatitis (MASH) based on clinical trial outcomes [127,128].”
Khan, I., Meenakshi, S., Abubakar, M., Kumar, N., Gaikwad, V. L., Rai, A., & Murti, K. (2026) · Endocrine · doi:10.1007/s12020-026-04686-5 · Cited by 2
“GLP-1R are the primary and most well-studied incretin receptors in the kidney [208 ].”
Metadata
- Authors
- Cooper, M. E., & van Raalte, D. H.
- Affiliations
- Monash University (AU)
- Diabetes Center, Department of Internal Medicine, Amsterdam University Medical Center, Amsterdam, Netherlands.
- Corresponding author
- Cooper, Mark E.
- ORCID
- Cooper, Mark E.
- Venue
- Journal of Clinical Investigation
- Published
- 2025-11-03
- Volume
- 135
- Issue
- 21
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC12578383
- OpenAlex
- W4415854994
- Semantic Scholar
- 5f04c667298e09c33f3fbc24adfb4ab50611f6dd
- Cited by
- 24
- References
- 90
- Citations by year
- 2026: 24
- FWCI
- 3.24
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Clinical Investigation (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- Eli Lilly and Company
- AstraZeneca
- Monash University
- Nierstichting
- Ministerio de Economía y Competitividad
- Novo Nordisk
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Keywords
- GLP-1 receptor agonists, glucagon-like peptide-1, chronic kidney disease, type 2 diabetes, obesity, renal protection, renal function, insulin resistance, weight loss
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Animals, Diabetes Mellitus, Type 2, Diabetic Nephropathies, Humans, Hypoglycemic Agents, Obesity, Renal Insufficiency, Chronic, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: GLP-1 agonists in the treatment of chronic kidney disease in type 2 diabetes and obesity. https://app.cochat.ai/papers/10.1172/jci194749
- The paper
- Cooper, M. E., & van Raalte, D. H. (2025). GLP-1 agonists in the treatment of chronic kidney disease in type 2 diabetes and obesity. Journal of Clinical Investigation. https://doi.org/10.1172/jci194749
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.